COSTEM 2019 | The “controversial situations” seen in FLT3-mutated AML patients

Lars Bullinger

Lars Bullinger, MD, Charité University of Medicine, Berlin, Germany, discusses the controversial situations seen in FLT3-mutated acute myeloid leukemia (AML) and the use of the new drug midostaurin. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video